Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...

Mike Braun and Eli Lilly officials broke ground Tuesday on one of the first major projects for the LEAP District. Company ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

A former Boone County bean field is where Lilly will research, develop, and manufacture the medicines of the future. Company ...

Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of ...

Eli Lilly and Co. will break ground on its $4.5 billion Lilly Medicine Foundry in Lebanon, Indiana's LEAP Research and Innovation District. The foundry could bring in 400 highly skilled workers to ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...